Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age

Trial Profile

A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Influenza virus vaccine live (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Oct 2018 Primary endpoint has been met. (Proportion of subjects with strain-specific hemagglutination inhibition seroconversion rates)
    • 07 Oct 2018 Results presented at the IDWeek 2018
    • 21 Feb 2018 According to an AstraZeneca media release, full results from this trial will be presented at a forthcoming medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top